Impact of formulary management and step therapy for non-sedating antihistamines on prescription drug utilisation and costs

References

• National Institute for Health Care Management Research and Educational Foundation. Prescription drug expenditures in 2001: another year of escalating costs. Available at: http://www.nihcm.org/nihcmor/pdf/spending2001.pdf [last accessed 15 June 2007].
   Google Scholar
• Segedin DA. Three-tier copayment plans: design considerations and effectiveness. Drug Benefits Trends 1999; 11: 43–52
   Google Scholar
• Penna P. Three-tier copayment systems and consumer concentric care. Journal of Managed Care Pharmacy 2000; 6: 351–354
   Google Scholar
• Schoenwetter WF. Allergic rhinitis: epidemiology and natural history. Allergy and Asthma Proceedings 2000; 21: 1–6
   PubMed Web of Science ®Google Scholar
• McCrory DC, Williams JW, Dolor RJ, et al. Management of Allergic Rhinitis in the Working-Age Population. Agency for Healthcare Research and Quality (AHRQ), March Report No. 67., Washington, DC
   Google Scholar
• Malone DC, Lawson KA, Smith DH, et al. Cost of illness study of allergic rhinitis in the United States. Journal of Allergy and Clinical Immunology 1997; 99: 22–27
   PubMed Web of Science ®Google Scholar
• Segura T, Casale TB. Allergic rhinitis: basic pathophysiology and therapeutic strategies. Canadian Journal of Allergy and Clinical Immunology 1999; 4: 318–330
   Google Scholar
• US Food and Drug Administration. FDA approves OTC Claritin. Available at: http://www.fda.gov/bbs/topics/NEWS/2002/NEW00855.html [last accessed 15 June 2007].
   Google Scholar
• Oregon Health and Science University. Drug Effectiveness Review Project. Drug class review on newer antihistamines. Final Report Update 1. Available at: http://www.ohsu.edu/drugeffectiveness/reports/final.cfm [last accessed 15 June 2007].
   Google Scholar
• Sullivan PW, Nair KV, Patel BV. The effect of Rx-to-OTC switch of loratadine and changes in prescription drug benefits on utilization and cost of therapy. American Journal of Managed Care 2005; 11: 374–382
   PubMed Web of Science ®Google Scholar
• Sullivan PW, Follin SL, Nichol MB. Transitioning the second-generation antihistamines to over-the-counter status: a cost-effectiveness analysis. Medical Care 2003; 41: 1382–1395
   PubMed Web of Science ®Google Scholar
• Sullivan PW, Nichol MB. The economic impact of payer policies after the Rx-to-OTC switch of second-generation antihistamines. Value in Health 2004; 7: 402–412
   PubMed Web of Science ®Google Scholar
• Nair KV, Sullivan PW. Therapeutic and economic consequences of the OTC conversion of loratadine. Annals of Pharmacotherapy 2004; 38: 169–171
   PubMed Web of Science ®Google Scholar
• Trygstad TK, Hansen RA, Wegner SE. Evaluation of product switching after a state Medicaid program began covering loratadine OTC 1 year after market availability. Journal of Managed Care Pharmacy 2006; 12: 108–120
   PubMed Web of Science ®Google Scholar
• Bender BG, Berning S, Dudden R, et al. Sedation and performance impairment of diphenhydramine and second-generation antihistamines: a meta-analysis. Journal of Allergy and Clinical Immunology 2003; 111: 770–776
   PubMed Web of Science ®Google Scholar
• Horak F, Stubner UP. Comparative tolerability of second-generation antihistamines. Drug Safety 1999; 20: 385–401
   PubMed Web of Science ®Google Scholar
• Consumer Reports Best Buy Drugs. Treating allergies, hay fever, and hives: the antihistamines. Available at: http://www.crbestbuydrugs.org/drugreport_DR_Antihis.shtml [last accessed 15 June 2007].
   Google Scholar
• Pharmacy Benefit Insider. MCOs promote OTC loratadine, make formulary changes. Managed Pharmaceutical Report, March 2003. Available at: http://www.rxsolutions.com/c/pbi/pbi_view.asp?docid=322 [last accessed 15 June 2007].
   Google Scholar
• Kaiser Family Foundation. 2002 Employer Health Benefits Survey. Kaiser Family Foundation, Menlo Park, CA 2002
   Google Scholar
• Motheral BR, Henderson R, Cox ER. Plan-sponsor savings and member experience with point-of-service prescription step therapy. American Journal of Managed Care 2004; 10: 457–464
   PubMed Web of Science ®Google Scholar
• Curtiss FR. Outcomes of sword swallowing and pharmaceutical step-therapy interventions. Journal of Managed Care Pharmacy 2007; 13: 284–286
   PubMed Web of Science ®Google Scholar
• Gleason PP. Assessing step-therapy programs: a step in the right direction. Journal of Managed Care Pharmacy 2007; 13: 273–275
   PubMed Web of Science ®Google Scholar
• Dunn JD, Cannon HE, Mitchell MP, et al. Utilization and drug cost outcomes of a step-therapy edit for generic antidepressants in an HMO in an integrated health system. Journal of Managed Care Pharmacy 2006; 12: 294–302
   PubMed Web of Science ®Google Scholar
• Yokoyama K, Yang W, Preblick R, et al. Effects of a step-therapy program forangiotensin receptor blockers on antihypertensive medication utilization patterns and cost of drug therapy. Journal of Managed Care Pharmacy 2007; 13: 235–244
   PubMed Web of Science ®Google Scholar
• American Academy of Allergy, Asthma & Immunology. Insurance Coverage for H1-Antihistamines: implications for quality healthcare and public safety. American Academy of Allergy, Asthma & Immunology, Milwaukee, WI 2002
   Google Scholar
• Kailash SC, Bohn RL, Avorn J. Policy analysis of the conversion of histamine2-receptor antagonists to over-the-counter use. Medical Care 1997; 35: 32–48
   PubMed Web of Science ®Google Scholar
• Andrade SE, Gurwitz JH, Fish LS. The effect of Rx-to-OTC switch on medication prescribing patterns and utilization of physician services: the case of histamine2-receptor antagonists. Medical Care 1999; 37: 424–430
   PubMed Web of Science ®Google Scholar
• Carlsen KH, Kramer J, Fagertun HE, et al. Loratadine and terfenadine in perennial allergic rhinitis. Treatment of nonresponders to the one drug with the other drug. Allergy 1993; 48: 431–436
   PubMed Web of Science ®Google Scholar